activ
thrombot
complement
system
main
recognit
effector
mechan
multipl
advers
biolog
respons
trigger
biomateri
therapeut
cell
come
blood
contact
creat
surfac
autoprotect
human
innat
immun
combin
three
fundament
differ
strategi
develop
us
previous
shown
induc
substanti
incomplet
hemocompat
use
separ
summari
conjug
factor
h
bind
peptid
adpdegrad
enzym
use
peg
linker
materi
cellular
surfac
expos
human
whole
blood
factor
h
specif
recruit
modifi
surfac
inhibit
complement
attack
addit
activ
platelet
coagul
effici
attenu
degrad
adp
thu
inhibit
thromboinflamm
use
multicompon
approach
creat
hybrid
surfac
potenti
greatli
reduc
incompat
reaction
involv
biomateri
transplant
function
evalu
apyras
erythrocytesatp
assay
rabbit
apyraseerythrocyt
cellsml
suspend
pb
contain
atp
incub
min
centrifug
atp
concentr
supernat
determin
luciferasebas
atp
kit
biothema
handen
sweden
accord
manufactur
protocol
platelet
aggreg
test
aggregometryblood
drawn
collect
tube
contain
citrat
greiner
bioon
gmbh
kremsmuenst
austria
centrifug
min
prepar
plateletrich
plasma
prp
apyraseerythrocyt
erythrocyt
cell
prp
mix
prp
solut
adp
ad
prp
light
transmitt
monitor
aggregomet
dynabyt
medic
munich
germani
slidechamb
model
develop
group
use
evalu
function
peptid
substrat
cell
surfac
human
whole
blood
chamber
bloodcollect
materi
coat
heparin
accord
corlin
method
corlin
system
ab
uppsala
nilsson
et
al
modern
medicin
artifici
materi
frequent
come
contact
blood
tissu
fluid
eg
extracorpor
circul
devic
use
hemodialysi
hemofiltr
cardiopulmonari
bypass
cpb
extracorpor
membran
oxygen
ecmo
plasmapheresi
contact
induc
sequenc
event
involv
protein
adsorpt
inflammatori
reaction
includ
activ
complement
coagul
system
adhes
immunocompet
cell
expos
surfac
event
result
seriou
thromboinflammatori
incompat
reaction
target
implant
materi
exampl
hemodialysi
patient
risk
myocardi
infarct
time
higher
healthi
individu
chronic
wholebodi
inflamm
trigger
hemodialysi
like
contribut
arteriosclerosi
urem
patient
associ
significantli
decreas
life
expect
also
cpb
ecmo
procedur
increas
past
decad
result
vascular
bypass
surgeri
longlast
infect
affect
lung
eg
swine
influenza
sever
acut
respiratori
syndrom
sar
associ
side
effect
relat
contact
blood
materi
surfac
result
cellular
humor
defenc
reaction
known
system
inflammatori
respons
syndrom
sir
addit
small
implant
within
bloodstream
react
cascad
system
blood
instead
system
reaction
interact
produc
deleteri
effect
vascular
stent
elicit
fibrosi
restenosi
thrombosi
implant
site
cardiac
aid
pump
trigger
thrombot
reaction
lead
emboli
simultan
activ
innat
immun
thrombot
cascad
also
occur
transplant
cell
islet
langerhan
mesenchym
stemstrom
cell
msc
hepatocyt
graft
loss
result
part
thromboinflammatori
instant
bloodmedi
inflammatori
reaction
ibmir
reaction
consist
innat
immun
attack
trigger
activ
complement
coagul
system
follow
rapid
bind
activ
platelet
infiltr
polymorphonuclear
leukocyt
pmn
correspond
reaction
wholeorgan
transplant
ischemiareperfus
injuri
xenogenicallogen
antibodymedi
reject
major
mediat
cell
damag
transplant
also
trigger
complement
activ
thrombot
reaction
thu
import
make
surfac
artifici
materi
transplant
cell
inert
activ
innat
immun
thrombot
cascad
regul
thromboinflamm
group
studi
regul
coagulationplatelet
complement
system
biomateri
surfac
use
variou
approach
nilsson
et
al
success
immobil
adpdegrad
apyras
substrat
surfac
inhibit
platelet
activ
plateletdepend
activ
coagul
system
recent
also
identifi
peptid
high
affin
variou
domain
human
factor
h
abund
plasma
protein
regul
complement
activ
solut
selfsurfac
one
peptid
recruit
factor
h
without
interf
regulatori
function
sinc
bound
region
regul
interact
convertas
describ
creation
combin
surfac
coat
autoregulatori
thromboinflamm
surfac
modif
apyras
appli
onto
substrat
artifici
materi
cell
amphiphil
polym
poli
ethylen
glycol
conjug
phospholipid
peglipid
coimmobil
apyras
cell
surfac
outlin
fig
peglipid
deriv
immobil
cell
membran
hydrophob
interact
lipid
bilay
membran
without
either
cytotox
volum
increas
far
previous
studi
effect
surfac
modif
live
cell
islet
peglipid
deriv
graft
surviv
cell
transplant
end
peg
deriv
face
fluid
phase
function
allow
bind
peptid
protein
oligonucleotid
peglipid
deriv
abl
suppress
coagul
inflammatori
reaction
ibmir
certain
extent
paper
perform
variou
assay
evalu
apyras
function
detect
complementactiv
marker
modifi
surfac
hemolyt
assay
complement
altern
pathway
ap
xenogen
biocompat
assay
adher
porcin
aortic
endotheli
cell
paec
contact
human
whole
blood
biotinyl
factor
hhuman
factor
h
prepar
human
serum
biotinyl
factor
h
perform
use
biotinamidohexano
acid
nhydroxysuccinimid
ester
sigmaaldrich
inc
st
loui
usa
solut
factor
h
pb
mix
biotinamidohexano
acid
nhydroxysuccinimid
ester
mm
dmso
min
room
temperatur
rt
follow
dialysi
pb
overnight
synthesi
factor
hbind
peptid
control
peptideanalog
factor
hbind
peptid
asssrctyshwcsh
prepar
use
solid
phase
peptid
synthesi
spp
cycliz
via
oxid
cystein
residu
describ
previous
surfac
attach
sequenc
expend
cterminu
short
spacer
group
peg
follow
either
free
cystein
lysin
residu
biotin
moieti
attach
spp
inact
linear
control
peptid
base
scrambl
sequenc
sc
yssswahastrash
prepar
modifi
describ
scci
scbiotin
ident
puriti
peptid
verifi
hplc
mass
spectrometri
puriti
peptid
peptid
immobil
polystyren
surfacepolystyren
microtit
plate
maxisorp
nunc
roskild
denmark
coat
avidin
sigmaaldrich
incub
overnight
surfac
block
incub
vv
tween
pb
min
biotinyl
peptid
scbiotin
pb
subsequ
bound
avidin
layer
incub
min
rt
surfac
extens
wash
pb
peptid
immobil
glass
surfacesglass
slide
wash
sigmaaldrich
inc
pure
water
immers
triethoxysilan
apt
sigmaaldrich
inc
toluen
solut
h
rt
wash
ethanol
pure
water
dri
vacuo
overnight
result
aptesco
glass
slide
poli
ethylen
glycol
malpegnh
peg
kda
nof
corpor
tokyo
japan
dissolv
dichloromethan
mgml
sigmaaldrich
ad
aptesco
glass
slide
incub
day
rt
gentl
shake
sequenti
wash
dichloromethan
ethanol
pure
water
malpegmodifi
surfac
expos
solut
scci
variou
concentr
pb
h
conjug
peptid
end
peg
chain
thiolmaleimid
reaction
peptideimmobil
surfac
use
experi
wash
pb
bind
factor
h
peptideimmobil
surfacebind
factor
h
scimmobil
polystyren
surfac
examin
incub
lepirudinanticoagul
plasma
shere
ag
saksa
germani
dilut
seri
variou
period
time
plasma
dilut
threefold
dilut
veronalbuff
salin
ph
contain
mm
ca
mm
mg
vb
incub
min
agit
plasma
dilut
vb
also
incub
min
bind
factor
h
detect
sheep
antifactor
h
bind
site
group
ltd
birmingham
uk
dilut
pbstween
bsa
peroxidas
hrp
conjug
rabbit
antisheep
ig
dako
dilut
pbstween
bsa
bind
evalu
incub
tmb
substrat
chromogen
dako
glostrup
denmark
absorb
read
nm
examin
bind
factor
h
peptideimmobil
glass
surfac
peptid
concentr
surfac
block
bsa
mgml
h
rt
incub
biotinfactor
h
pb
h
rt
wash
pb
hrpconjug
streptavidin
ge
healthcar
uppsala
sweden
ad
min
follow
sequenti
incub
tmb
substrat
chromogen
dako
bound
factor
h
character
western
blot
analysi
lepirudin
plasma
nativ
dilut
pb
incub
scimmobil
polystyren
surfac
min
extens
wash
bound
protein
elut
use
electrophoresi
sampl
buffer
contain
sd
sampl
subject
sdspage
reduc
condit
follow
western
blot
analysi
use
sheep
antifactor
h
bind
site
dilut
hrpconjug
rabbit
antisheep
igg
dako
dilut
evalu
complement
activ
peptidesurfac
plasma
whole
bloodblood
drawn
healthi
volunt
receiv
medic
least
day
prior
blood
collect
blood
collect
vacutain
tube
anticoagul
lepirudin
final
concentr
complement
activ
examin
incub
whole
blood
scimmobil
microtit
plate
blood
edta
mm
mg
egta
mm
mix
mm
mg
pb
volum
correct
incub
peptideimmobil
surfac
min
activ
interrupt
addit
edta
mm
final
concentr
aliquot
whole
blood
use
analysi
remain
blood
centrifug
min
obtain
plasma
store
analyz
microtit
plate
wash
extens
pbstween
incub
rabbit
dako
dilut
hrpconjug
swine
antiigg
tmb
substrat
chromogen
dako
granulocyt
express
granulocyt
exposur
peptid
surfac
analyz
monoclon
mous
mab
dako
glostrup
denmark
clone
accord
manufactur
protocol
brief
incub
whole
blood
peptid
surfac
min
antibodi
ad
incub
min
erythrocyt
subsequ
lyse
akc
solut
mm
nh
cl
mm
khco
mm
edta
incub
min
leukocyt
isol
centrifug
min
pellet
wash
pb
bsa
resuspend
paraformaldehyd
pb
apoteket
gothenburg
sweden
analyz
cell
lab
quanta
sc
flow
cytomet
beckman
coulter
miami
fl
usa
granulocyt
gate
size
granular
fluoresc
intens
record
gate
cell
prepar
peglipid
peglipid
derivativesmethoxylpegconjug
phospholipid
meopeglipid
malpegconjug
phospholipid
malpeglipid
biotinpegconjug
phospholipid
biotinpeglipid
synthes
previous
describ
solut
sc
mgml
pb
mix
malpeglipid
mgml
pb
conjug
peptid
end
peg
chain
yield
scpeglipid
respect
biotinpeglipid
fitclabel
streptavidin
ge
healthcar
use
order
confirm
incorpor
peglipid
deriv
rabbit
erythrocyt
surfac
rabbit
erythrocyt
laboratori
sweden
pb
mix
biotinpeglipid
pb
min
rt
fitcstreptavidin
dilut
pb
ad
incub
min
wash
pb
erythrocyt
examin
use
confoc
laser
scan
microscopi
meta
carl
zeiss
jena
germani
hemolyt
assay
ap
perform
use
rabbit
erythrocyt
modifi
scpeglipid
examin
effect
peptid
incorpor
cell
membran
mixtur
meopeglipid
meopeglipid
scpeglipid
molar
ratio
use
surfac
modif
rabbit
erythrocyt
total
concentr
peglipid
mgml
respect
first
rabbit
erythrocyt
wash
pb
supernat
clear
solut
peglipid
mixtur
ad
erythrocyt
incub
min
rt
gentl
mix
follow
wash
mg
egta
buffer
mm
egta
mm
mgso
gl
gelatin
veronalbuff
salin
ph
ice
three
time
suspens
rabbit
erythrocyt
mix
human
serum
mg
egta
buffer
shaken
h
supernat
collect
centrifug
absorb
supernat
nm
measur
calcul
percentag
erythrocyt
lyse
incub
human
serum
erythrocyt
collect
incub
dilut
antihuman
factor
h
antibodi
min
rt
wash
pb
incub
dilut
antisheep
igg
invitrogen
carlsbad
ca
usa
analysi
confoc
laser
scan
microscopi
fac
bd
lsrii
facscalibur
bd
bioscienc
san
jose
ca
usa
immobil
apyras
erythrocyt
malpeglipidapyras
immobil
surfac
erythrocyt
human
rabbit
use
malpeglipid
previous
report
thiol
group
introduc
apyras
thiolat
use
traut
reagent
thermo
fisher
scientif
waltham
usa
apyras
solut
mgml
potato
sigmaaldrich
mix
traut
reagent
mgml
solut
incub
gentl
mix
rt
h
thiolat
apyras
apyrasesh
purifi
use
spin
column
thermo
fisher
scientif
order
visual
examin
immobil
apyras
erythrocyt
surfac
use
apyrasesh
prior
thiolat
traut
reagent
apyras
label
alexa
use
label
kit
invitrogen
accord
manufactur
protocol
erythrocyt
cell
incub
solut
malpeglipid
mgml
pb
min
rt
wash
three
time
cold
pb
obtain
erythrocyt
modifi
malpeglipid
malpegerythrocyt
obtain
apyraseerythrocyt
malpegerythrocyt
mix
apyrasesh
solut
pb
left
min
rt
wash
cold
pb
three
time
sweden
whole
blood
seven
healthi
donor
collect
heparinco
tube
contain
solubl
heparin
leo
pharma
ballerup
denmark
final
concentr
iu
heparinml
human
apyraseerythrocyt
mix
whole
blood
final
concentr
blood
ml
ad
well
slide
chamber
cover
poli
vinyl
chlorid
plate
addit
blood
mix
pegerythrocyt
final
concentr
apyras
alon
without
addit
use
control
chamber
rotat
vertic
rpm
min
water
bath
ml
blood
collect
well
mix
edtak
solut
final
concentr
mm
platelet
concentr
analyz
coulter
act
hematolog
analyz
coulter
corpor
miami
fl
usa
blood
centrifug
min
plasma
collect
store
analysi
enzym
immunoassay
eia
thrombinantithrombin
complex
tat
immobil
apyras
onto
substratesa
mix
solut
scci
apyrasesh
incub
malpegmodifi
substrat
h
immobil
peptid
apyras
treat
surfac
use
experi
wash
pb
apyras
activ
surfac
monitor
atp
assay
describ
slide
chamber
experi
use
whole
bloodwhol
blood
seven
healthi
donor
collect
heparinco
tube
without
solubl
heparin
incub
slide
chamber
describ
complement
activ
measur
exposur
paec
human
whole
blood
presenc
absenc
order
assess
function
peptid
mixtur
meopeglipid
molar
ratio
total
concentr
mgml
use
surfac
modif
paec
paec
kind
gift
prof
lena
claessonwelsh
cultur
invitrogen
supplement
fetal
bovin
serum
uml
penicillin
streptomycin
co
paec
cell
collect
centrifug
min
incub
trypsinedta
invitrogen
min
cell
seed
onto
aptesco
glass
slide
cultur
medium
day
order
examin
incorpor
peglipid
deriv
onto
surfac
adher
paec
use
biotinpeglipid
fitclabel
streptavidin
describ
paec
expos
biotinpeglipid
mgml
medium
min
rt
fitcstreptavidin
dilut
pb
ad
incub
min
pb
wash
paec
analyz
confoc
laser
scan
microscopi
adher
paec
expos
mixtur
meopeglipid
min
rt
follow
wash
medium
use
slide
chamber
experi
viabil
assay
perform
trypan
blue
exclus
test
viabil
paec
surfac
modif
surfac
modif
paec
cell
peptid
apyrasecel
seed
onto
aptesco
glass
slide
cultur
cultur
medium
day
paec
incub
peptidepeglipid
malpeglipid
mixtur
total
peglipid
mgml
peptidepeglipid
mol
min
rt
follow
wash
medium
incub
solut
apyrasesh
min
rt
paec
use
slidechamb
experi
wash
medium
prepar
apyraseimmobil
paec
paec
incub
solut
apyrasesh
treat
malpeglipid
mgml
min
rt
slidechamb
experi
use
whole
bloodwhol
blood
six
healthi
donor
collect
heparinco
tube
contain
solubl
heparin
final
concentr
iu
heparinml
well
chamber
fill
blood
ml
cover
glass
slide
whose
surfac
cover
paec
prepar
describ
chamber
rotat
vertic
rpm
min
water
bath
follow
platelet
count
collect
plasma
describ
exposur
paeccoat
glass
slide
whole
blood
wash
pb
immers
paraformaldehyd
apoteket
incub
antihuman
factor
h
antibodi
dilut
min
rt
pb
wash
incub
antisheep
igg
examin
confoc
laser
scan
microscopi
measur
tat
tat
plasma
measur
convent
sandwich
eia
solubl
plasma
dilut
work
buffer
pb
contain
tween
mgml
bsa
mm
edta
previous
report
captur
antihuman
mab
detect
biotinyl
polyclon
rabbit
antibodi
hrpconjug
streptavidin
zymosanactiv
serum
calibr
purifi
serv
standard
valu
express
ngml
analyz
commerci
kit
hycult
biotechnolog
uden
netherland
accord
protocol
sampl
dilut
valu
express
ngml
plasma
dilut
work
buffer
captur
antihuman
mab
diatec
monoclon
oslo
norway
detect
antihuman
polyclon
rabbit
antibodi
dako
hrpconjug
antirabbit
igg
dako
zymosanactiv
serum
contain
auml
serv
standard
valu
express
auml
tat
plasma
dilut
normal
citratephosphatedextros
plasma
tat
captur
antihuman
thrombin
mab
detect
hrpcoupl
antihuman
antithrombin
mab
enzym
research
laboratori
south
bend
usa
standard
prepar
dilut
pool
human
serum
normal
citratephosphatedextros
plasma
use
valu
express
statist
analysisresult
present
mean
sem
data
plot
statist
analysi
perform
use
prism
version
macintosh
softwar
graphpad
san
diego
ca
usa
differ
mean
two
group
statist
evalu
use
pair
student
ttest
repeat
measur
oneway
anova
dunnett
post
hoctest
two
group
compar
control
data
assum
normal
distribut
factor
hspecif
scrambl
control
sc
peptid
immobil
onto
polystyren
glass
surfac
biotinavidin
reaction
coval
thiolmaleimid
bond
via
peg
chain
respect
fig
b
modifi
surfac
compar
regard
factor
h
bind
lepirudin
plasma
purifi
form
coat
surfac
bound
significantli
higher
amount
compar
sc
bind
depend
peptid
densiti
supplement
fig
modifi
surfac
incub
lepirudinanticoagul
whole
blood
complement
activ
gener
granulocyt
activ
express
monitor
coat
significantli
reduc
complement
activ
maker
compar
control
lower
granulocyt
activ
via
ap
supplement
fig
taken
togeth
result
indic
factor
h
captur
immobil
surfac
suppress
complement
activ
human
whole
blood
next
incorpor
onto
erythrocyt
surfac
use
peglipid
deriv
could
anchor
cell
membran
hydrophob
interact
fig
peglipid
deriv
erythrocyt
detect
use
fluoresc
streptavidin
biotinpeglipid
supplement
fig
modifi
erythrocyt
incub
human
serum
subject
immunostain
factor
h
follow
fac
analysi
fig
supplement
fig
confoc
microscopi
reveal
fluoresc
stain
erythrocyt
surfac
modifi
treat
scpeglipidmeopeglipid
fac
analysi
yield
similar
result
next
perform
hemolyt
assay
examin
effect
complement
activ
via
ap
incub
rabbit
erythrocyt
human
serum
optim
concentr
coat
erythrocyt
surfac
determin
mix
inert
meopeglipid
differ
proport
uninhibit
condit
approxim
rabbit
erythrocyt
hemolyz
incub
human
serum
howev
lysi
calcul
fraction
lyse
suppress
surfac
modif
peglipid
reduc
presenc
compar
scmodifi
group
fig
supplement
fig
peglipid
concentr
increas
differ
erythrocyt
scimmobil
erythrocyt
becam
smaller
seen
fig
effect
peg
also
seen
clearli
surfac
densiti
peg
larger
optim
condit
abl
specif
recruit
function
factor
h
human
serum
suppress
apmedi
complement
activ
erythrocyt
surfac
paec
cultur
aptesco
glass
slide
confluenc
incorpor
paec
use
peglipid
expos
blood
contain
iu
heparinml
slide
chamber
model
fluoresc
could
observ
peripheri
adher
cell
treatment
biotinpeglipid
fitcstreptavidin
cell
detach
substrat
surfac
supplement
fig
paec
treat
mixtur
meopeglipid
total
peglipid
concentr
mgml
expos
human
whole
blood
exposur
blood
paec
subject
immunostain
factor
h
supplement
fig
could
detect
paec
surfac
modifi
gener
paec
surfac
modifi
meopeglipid
gener
lower
compar
control
paec
indic
peg
coat
protect
cell
surfac
complement
activ
howev
significantli
greater
reduct
marker
seen
presenc
paec
surfac
optim
effect
peptid
concentr
supplement
fig
contrast
platelet
count
decreas
either
control
paec
paec
modifi
peglipid
differ
seen
tat
due
presenc
heparin
suppress
coagul
supplement
fig
collect
result
indic
abl
specif
recruit
factor
h
human
blood
therebi
suppress
complement
activ
paec
surfac
next
immobil
apyras
erythrocyt
use
malpeglipid
shown
fig
fluoresc
clearli
observ
peripheri
erythrocyt
treat
malpeglipid
treat
alon
fig
morpholog
chang
observ
immobil
apyras
effect
erythrocytebound
apyras
atp
decay
adpinduc
platelet
aggreg
test
apyraseimmobil
erythrocyt
degrad
exogen
ad
atp
dosedepend
manner
fig
addit
adpinduc
platelet
aggreg
effect
suppress
presenc
apyraseerythrocyt
wherea
suppress
seen
nonmodifi
erythrocyt
fig
result
indic
apyras
immobil
retain
activ
human
whole
blood
rotat
slide
chamber
platelet
count
gradual
decreas
time
reflect
coagul
platelet
activ
less
decreas
platelet
count
whole
blood
mix
apyraseerythrocyt
apyras
wherea
pegerythrocyt
show
reduct
similar
whole
blood
supplement
fig
tat
gener
follow
similar
trend
supplement
fig
contrast
differ
complement
activ
marker
among
group
supplement
fig
indic
immobil
apyras
affect
complement
result
demonstr
whole
blood
apyras
immobil
cell
surfac
abl
inhibit
platelet
activ
well
suppress
coagul
activ
apyras
coimmobil
onto
substrat
surfac
investig
combin
effect
initi
examin
atpas
activ
surfac
ensur
apyras
inhibit
presenc
supplement
fig
coimmobil
substrat
surfac
expos
blood
slide
chamber
platelet
consumpt
significantli
lower
scapyras
apyraseimmobil
surfac
control
peg
surfac
fig
tat
level
show
similar
trend
indic
coimmobil
apyras
suppress
activ
platelet
coagul
fig
marker
complement
activ
significantli
reduc
surfac
compar
scapyras
apyras
peg
surfac
fig
indic
complement
activ
suppress
coimmobil
surfac
final
cell
surfac
paec
modifi
peptid
apyras
use
malpeglipid
fig
adher
paec
test
slidechamb
model
platelet
consumpt
tat
level
significantli
lower
scapyraseand
apyrasemodifi
cell
surfac
control
paec
surfac
fig
b
addit
significantli
reduc
modifi
cell
surfac
compar
group
fig
factor
h
could
detect
immunostain
paec
surfac
modifi
apyras
fig
collect
result
show
factor
h
recruit
surfac
substrat
paec
surfac
modifi
suppress
coagul
complement
activ
whole
blood
paper
demonstr
two
human
wholeblood
model
activ
platelet
coagul
complement
system
control
simultan
coimmobil
factor
hbind
peptid
apyras
biomateri
cell
surfac
complement
system
control
regul
complement
activ
rca
mainli
regul
classic
pathway
cp
ap
convertas
addit
plasma
membran
regul
mcp
daf
plasma
protein
protein
factor
h
also
regul
surfacebound
cp
ap
convertas
respect
fluidphas
regul
recruit
host
cell
bind
cellsurfac
glyocosaminoglycan
regul
complement
activ
cp
ap
respect
concept
exploit
complementregulatori
effect
foreign
surfac
demonstr
group
engberg
et
al
use
streptococc
proteinderiv
peptid
specif
recruit
human
substrat
surfac
therebi
reduc
complement
activ
via
cp
suggest
rcabind
peptid
promis
regul
complement
activ
cell
materi
surfac
sever
studi
indic
complement
activ
materi
surfac
initi
cp
howev
ap
convertas
major
import
abil
amplifi
reaction
surfac
therebi
trigger
variou
inflammatori
reaction
therefor
seem
major
import
regul
ap
convertas
order
avoid
complement
attack
earlier
examin
possibl
suppress
complement
activ
ap
coval
immobil
factor
h
substrat
surfac
although
approach
promis
limit
first
protein
bind
randomli
surfac
fraction
protein
maintain
activ
conform
second
larg
amount
factor
h
need
coat
surfac
approach
cell
materi
specif
recruit
factor
h
host
blood
therebi
mimick
host
surfac
protect
attack
complement
coat
small
peptid
also
allow
us
avoid
costli
cumbersom
prepar
immobil
recombin
protein
use
avoid
random
bind
protein
instead
obtain
consist
orient
configur
protein
optim
surfac
densiti
hemolyt
assay
found
maximum
indic
spatial
requir
interact
factor
h
presum
sinc
factor
h
function
domain
region
termini
access
may
limit
steric
hindranc
higher
densiti
platelet
intim
involv
incompat
process
occur
foreign
surfac
directli
activ
surfac
platelet
close
connect
coagul
cascad
also
interact
leukocyt
trigger
activ
complement
therebi
act
import
hub
mediat
crosstalk
compon
platelet
activ
multistep
process
begin
involv
adhes
aggreg
contract
secret
releas
adp
essenti
recruit
aggreg
platelet
therefor
obviou
target
platelet
inhibit
order
regul
platelet
activ
vascular
adp
continu
degrad
homeostat
condit
ec
enzym
present
human
endotheli
cell
present
studi
use
homolog
potato
apyras
prototyp
enzym
obtain
proofofconcept
group
enzym
valuabl
tool
attenu
thrombot
reaction
materi
cell
surfac
recent
studi
shown
antiinflammatori
immunosuppress
extracellular
adenosin
signal
modul
neutrophil
accumul
particularli
condit
acut
injuri
eg
ambient
hypoxia
condit
extracellular
adenosin
mainli
deriv
enzymat
phosphohydrolysi
precursor
nucleotid
adenosin
twostep
enzymat
process
involv
ectoapyras
convert
atpadp
amp
nucleotidas
convert
amp
adenosin
enzym
implic
attenu
acut
injuri
inflamm
model
ambient
hypoxia
cyclic
mechan
stretch
bleomycininduc
lung
injuri
studi
mice
identifi
import
role
enzym
control
acut
immun
respons
mice
demonstr
exacerb
inflamm
experiment
model
hypoxia
endotoxininduc
lung
inflamm
coliti
similarli
human
carri
singl
specif
point
mutat
gene
recent
shown
suscept
inflammatori
bowel
diseas
studi
suggest
use
would
also
antiinflammatori
immunosuppress
effect
cell
wholeorgan
transplant
summari
combin
coat
consist
three
major
compon
protect
underli
surfac
peg
linker
factor
hbind
peptid
adpdegrad
apyras
factor
h
specif
recruit
surfac
inhibit
complement
attack
expos
human
whole
blood
addit
activ
platelet
coagul
effici
attenu
degrad
adp
thu
inhibit
thromboinflamm
use
multicompon
approach
creat
hybrid
surfac
potenti
greatli
reduc
incompat
reaction
involv
biomateri
therapeut
cell
refer
web
version
pubm
central
supplementari
materi
represent
cell
surfac
modifi
apyras
coimmobil
cell
surfac
incorpor
lipid
bilay
membran
factor
h
recruit
surfac
human
blood
impair
complement
activ
apyras
degrad
adp
suppress
platelet
coagul
activ
